Harriet Kang
Neurology · Hartsdale, NYNPI 1235192683
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,200 of the $11,098 with a category attached, or 64.9%. UCB SA accounts for 64.9% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2020 at $6,189 and has fallen 96.8% since, to $198 in 2025.
Across 91 payments — averaging $121.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB SA$7K
- Greenwich Biosciences, Inc.$674
- Jazz Pharmaceuticals Inc.$655
- Immedica Pharma US, Inc.$416
- Neurelis, Inc.$408
- UCB, Inc.$401
- plus $1K from 19 others
Across 50 payments — averaging $6953.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$133K
- Aquestive Therapeutics, Inc.$117K
- Zogenix Inc.$41K
- Eisai Inc.$39K
- Neurelis, Inc.$12K
- UCB, Inc.$4K
- plus $2K from 1 others
What the payments were for
- Consulting fees$7,20065%
- Food & beverage$3,89835%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB SA | 2 | $7,200 |
| Greenwich Biosciences, Inc. | 7 | $674 |
| Jazz Pharmaceuticals Inc. | 19 | $655 |
| Immedica Pharma US, Inc. | 10 | $416 |
| Neurelis, Inc. | 6 | $408 |
| UCB, Inc. | 7 | $401 |
| Aquestive Therapeutics, Inc. | 5 | $238 |
| SK Life Science, Inc. | 6 | $229 |
| Sunovion Pharmaceuticals Inc. | 4 | $221 |
| Biocodex, Inc. | 2 | $102 |
| Monteris Medical Corporation | 2 | $98 |
| Ironshore Pharmaceuticals Inc. | 4 | $80 |
| Livanova USA, Inc. | 2 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $46 |
| Zimmer Biomet | 1 | $36 |
| Tris Pharma Inc | 2 | $35 |
| Neuropace, Inc. | 1 | $34 |
| Aucta Pharmaceuticals, Inc. | 3 | $26 |
| Eisai Inc. | 1 | $25 |
| Vertical Pharmaceuticals, LLC | 1 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $22 |
| Supernus Pharmaceuticals, Inc. | 1 | $20 |
| Catalyst Pharmaceuticals, Inc. | 1 | $19 |
| Mallinckrodt Enterprises LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,098 in reported general payments places this provider in the 75th percentile of 1,623 neurology providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Zonisamide | 13 | $255 |
| Clobazam | 11 | $251 |
Paid to pharmacies, not to this prescriber.
Other neurology in Hartsdale
- Idan SharonBrooklyn$2.1M
- Allan PerelStaten Island$1.7M
- Nicolas SaikaliAmherst$1.5M
- David KreitzmanCommack$1.5M
- Charles ArgoffAlbany$1.2M
- Stephen KriegerNew York$1.1M
- Robert FeketeHawthorne$1M
- Jennifer McVigeAmherst$982K
- Warren SpinnerPort Jefferson Station$791K
- Richard LiptonBronx$753K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.